Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
OnKure Therapeutics, Inc. (OKUR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: OKUR (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit 119.59% | Avg. Invested days 34 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 76.57M USD | Price to earnings Ratio 71.75 | 1Y Target Price 34.2 |
Price to earnings Ratio 71.75 | 1Y Target Price 34.2 | ||
Volume (30-day avg) 30663 | Beta - | 52 Weeks Range 4.11 - 20.00 | Updated Date 04/1/2025 |
52 Weeks Range 4.11 - 20.00 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.08 |
Earnings Date
Report Date 2025-03-11 | When - | Estimate - | Actual -2.755 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE 71.75 | Forward PE - | Enterprise Value 565252 | Price to Sales(TTM) - |
Enterprise Value 565252 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.57 | Shares Outstanding 12652900 | Shares Floating 4190656 |
Shares Outstanding 12652900 | Shares Floating 4190656 | ||
Percent Insiders 1.45 | Percent Institutions 96.85 |
Analyst Ratings
Rating 4.75 | Target Price - | Buy 1 | Strong Buy 3 |
Buy 1 | Strong Buy 3 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
OnKure Therapeutics, Inc.
Company Overview
History and Background
OnKure Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing innovative medicines to treat cancer. While specific founding details are not widely available, they are a clinical-stage company with programs targeting key cancer pathways.
Core Business Areas
- Drug Development: Focuses on the discovery and development of small molecule therapeutics for cancer treatment. This includes pre-clinical research, clinical trials, and regulatory submissions.
- Clinical Trials: Conducts clinical trials to evaluate the safety and efficacy of their drug candidates in various cancer types.
- Commercialization: Aims to commercialize their approved therapies through partnerships or direct sales.
Leadership and Structure
Information on the specific leadership team and organizational structure of OnKure Therapeutics, Inc. is generally available on their corporate website and investor relations pages.
Top Products and Market Share
Key Offerings
- OKI-179: A selective PI3Ku03b1 inhibitor in Phase 1b clinical trials for advanced solid tumors. Market share data not publicly available. Competitors include other PI3K inhibitors from companies like Novartis (NVS), Bayer (BAYRY), and Roche (RHHBY).
- OKI-219: A novel small molecule in preclinical development, targeting a novel cancer target. Market share data not publicly available as it is in preclinical. Competitors are dependent on the specific target addressed.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high R&D costs, lengthy regulatory approval processes, and intense competition. The oncology market is a major segment, driven by the increasing prevalence of cancer and advancements in targeted therapies and immunotherapies.
Positioning
OnKure Therapeutics, Inc. is positioned as an innovative drug developer focused on targeted therapies for cancer. Their competitive advantage lies in their novel drug candidates and expertise in specific cancer pathways.
Total Addressable Market (TAM)
The global oncology market is projected to reach hundreds of billions of dollars. OnKure Therapeutics, Inc. is targeting specific niches within this market with their novel therapies, aiming to capture a portion of the TAM.
Upturn SWOT Analysis
Strengths
- Novel drug candidates
- Targeted therapy approach
- Experienced management team
- Strong scientific expertise
Weaknesses
- Limited financial resources
- Dependence on clinical trial success
- Small company size
- No currently marketed products
Opportunities
- Partnerships with larger pharmaceutical companies
- Successful clinical trial outcomes
- Expansion into new cancer indications
- Acquisition by a larger company
Threats
- Clinical trial failures
- Competition from larger pharmaceutical companies
- Regulatory hurdles
- Patent expirations
Competitors and Market Share
Key Competitors
- NVS
- BAYRY
- RHHBY
Competitive Landscape
OnKure faces competition from established pharmaceutical companies with greater resources. Their advantage lies in their unique drug candidates and targeted approach.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Growth is primarily driven by progress in clinical trials and securing funding. No specific revenue growth data available.
Future Projections: Future growth depends on the successful development and commercialization of their drug candidates. Analyst estimates are not readily available due to the company's private status or limited public information.
Recent Initiatives: Recent initiatives likely include advancing their clinical trials for OKI-179 and progressing preclinical development of OKI-219.
Summary
OnKure Therapeutics is a clinical-stage biopharmaceutical company focusing on targeted cancer therapies. Its strengths lie in its novel drug candidates and focused approach, while weaknesses include limited financial resources and reliance on clinical trial success. Opportunities include partnerships and expansion into new indications, but threats include competition and regulatory hurdles. The future of OnKure hinges on successfully navigating the complex drug development and commercialization process.
Similar Companies
- NVS
- BAYRY
- RHHBY
Sources and Disclaimers
Data Sources:
- Company Website
- Publicly Available Clinical Trial Data
- Industry Reports
- Analyst Reports (if available)
Disclaimers:
This analysis is based on publicly available information and may not be entirely comprehensive. The biopharmaceutical industry is inherently risky, and past performance is not indicative of future results. Market share estimations are rough and for illustrative purposes only.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About OnKure Therapeutics, Inc.
Exchange NASDAQ | Headquaters Boulder, CO, United States | ||
IPO Launch date 2024-10-07 | President, CEO & Director Dr. Nicholas A. Saccomano Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 46 | Website https://onkuretherapeutics.com |
Full time employees 46 | Website https://onkuretherapeutics.com | ||
OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3 kinase alpha harboring the H1047R mutation that is in Phase 1 clinical trial for the treatment of solid tumors, including breast cancer. The company is headquartered in Boulder, Colorado.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.